2 Dividend Stocks to Buy Hand Over Fist in November was originally published by The Motley Fool Their recent issues are ...

AbbVie (NYSE:ABBV) shares traded in the red on Thursday, making it the seventh consecutive day of losses. The stock closed ...

Dividend stocks are attractive for their steady income, stability, and growth potential, especially amid low interest rates ...

S hould a high dividend yield raise a yellow flag for investors? In some cases, yes. But not always. There are select stocks ...

Discover how AbbVie investors that bought the anxiety over the loss of Humira exclusivity are sitting on massive gains. Read ...

However, arguably the next best thing is for a company to belong to the elite group known as Dividend Kings. To qualify, a ...

The added benefit is that AbbVie is a "Dividend King," which means it has consistently paid and increased dividends for the ...

As most advisors are well aware, high stock prices have pushed down the market’s dividend yield. Barron’s ran a screen for ...

AbbVie shares dropped nearly 10% after its schizophrenia drug emraclidine failed in late-stage trials. The market reaction ...

AbbVie reports disappointing mid-stage data for its schizophrenia drug. Jason Snipe of Odyssey Capital still likes AbbVie ...

AbbVie Inc. (NYSE: ABBV) is rewarding its shareholders once again with a quarterly dividend of $1.55, payable on Tuesday Oct. 15th. While investors will wait to hear about quarterly earnings on ...

AbbVie (NYSE: ABBV) continues to demonstrate its prowess in navigating the challenging landscape of drug development and ...